Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medical Innovation

NIH Accelerates the Use of Genomics Sequencing in Clinical Care

Bethesda, MD, October 13, 2017 — The National Institutes of Health (NIH) on August 8 announced it is awarding $18.9 million towards research that aims to accelerate the use of genome sequencing in clinical care.

The new awards will generate innovative approaches and best practices to ensure that the effectiveness of genomic medicine can be applied to all individuals and groups, including diverse and underserved populations, and in healthcare settings that extend beyond academic medical centers. Continue reading

PhRMA Announces 2017 Research & Hope Award Honorees; Releases ‘Medicines in Development for Mental Illnesses Report’

Washington, DC, October 11, 2017 — As part of Mental Health Awareness Week, Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday announced it is recognizing and honoring five individuals who are working tirelessly to advocate for patients, fight stigma surrounding mental illnesses and advance research at our 2017 Research & Hope Awards.

In addition, PhRMA said that America’s biopharmaceutical companies are committed to alleviating the considerable burden of mental illness and bringing cutting-edge medicines and new treatments to patients.

According to a new report — “Medicines in Development for Mental Illnesses 2017 Report” — released on October 10, there are more than 140 medicines in development to treat mental illnesses such as anxiety, depression, schizophrenia and more. Continue reading

Hackensack University Medical Center Foundation Receives Donation from Celgene to Advance Multiple Myeloma Research at John Theurer Cancer Center

Former Roche campus to be new Seton Hall-Hackensack Meridian School of Medicine

Hackensack, NJ, October 11, 2017 — The Hackensack University Medical Center Foundation announced on October 5 that it has received a substantial donation from Celgene Corporation to advance multiple myeloma research and transformational medicine that improve patient outcomes at Hackensack Meridian Health–John Theurer Cancer Center.

Supported by Celgene, a global biopharmaceutical leader in the discovery, development and delivery of treatment for diseases like multiple myeloma (MM), funds will help to establish the Multiple Myeloma Institute (MMI) — a leading-edge research facility at the Seton Hall-Hackensack Meridian School of Medicine scheduled to open in 2018.

Celgene and John Theurer Cancer Center are accomplished leaders in developing novel therapies for patients with multiple myeloma. Continue reading

American Cancer Society Report: Breast Cancer Death Rates Down 39 Percent Since 1989

Atlanta, GA, October 9, 2017 — A new report from the American Cancer Society finds that death rates from breast cancer in the United States have dropped 39% between 1989 and 2015.

This translates to 322,600 deaths avoided during those 26 years. African-American women still have higher breast cancer death rates than white women nationally.

The findings are published in Breast Cancer Facts & Figures 2017-2018 and in Breast Cancer Statistics, 2017 in CA: A Cancer Journal for Clinicians. Continue reading

NJBIA’s Innovation Summit 2017: Reinvent Your Business to Compete in the 21st Century Economy

Newark, NJ, October 5, 2017 — NJBIA’s Steve Wilson reports businesses need not be discouraged about the marketplace challenges of the 21st century economy. The innovation they need to take advantage of new technologies and new processes is well within their reach if they are willing to embrace change.

At NJBIA’s Innovation Summit on September 27, three long-established companies and the U.S. military showed how they are using innovation to not just survive, but to lead the way for change.

“We are about to go through an era that’s been called disruptive technology,” said Don Sebastian, president and CEO of the NJ Innovation Institute. “The cliff notes version is: You’re likely to become a dinosaur replaced by mammals.” Continue reading

Rutgers Research: Creating Brain Cells to Detect Tourette’s; First to Use Genetic Engineering Technique to Investigate Disease

New Brunswick, NJ, September 25, 2017 — Robin Lally reports that scientists at Rutgers University-New Brunswick are the first to use a genetic engineering technique to create brain cells from the blood cells of individuals in a three-generation family with Tourette syndrome to help determine what causes the disease.

“This is so important to the future research of Tourette’s and other neuropsychiatric disorders because before this technique was discovered we were unable to study brain-type nerve cells of living patients,” said Jay Tischfield, senior author of the study published in Molecular Psychiatry and MacMillan Distinguished Professor of Genetics.  Continue reading

Rutgers NJ Medical School Research: Memory Decline After Head Injury May be Prevented by Slowing Brain Cell Growth

New Brunswick, NJ, September 20, 2017 — Robin Lally reports on Rutgers Today that the excessive burst of new brain cells after a traumatic head injury that scientists have traditionally believed helped in recovery could instead lead to epileptic seizures and long-term cognitive decline, according to a new Rutgers New Jersey Medical School study.

In the September issue of Stem Cell Reports, Viji Santhakumar, Ph.D., associate professor in Department of Pharmacology, Physiology and Neuroscience, and her colleagues, challenge the prevailing assumption by scientists in the field that excessive neurogenesis (the birth of new brain cells) after injury is advantageous. Continue reading